Abstract:Haoqian Chen, 1 Xiao Zheng, 2, 3 Lingjue Li, 1 Lishuxin Huang, 1 Weiwei Huang, 2 Yanbing Ma 2 1 Key Laboratory of Chemistry in Ethnic Medicinal Resources, State Ethnic Affairs Commission & Ministry of Education, School of Ethnic Medicine, Yunnan Minzu University, Kunming, People's Republic of China; 2 Laboratory of Molecular Immunology, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, People's Republic of China; 3 School of Life Sciences, Yunnan University, Kunming, People's Republic of China Correspondence: Lishuxin Huang, Key Laboratory of Chemistry in Ethnic Medicinal Resources, State Ethnic Affairs Commission & Ministry of Education, School of Ethnic Medicine, Yunnan Minzu University, Kunming, 650504, People's Republic of China, Tel/Fax +86 871 6592 6040, Email Yanbing Ma, Laboratory of Molecular Immunology, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 935 Jiaoling Road, Kunming, 650032, People's Republic of China, Tel +86 871 6833 9287, Fax +86 871 6833 4483, Email Background: Peptide-based vaccines have broad application prospects because of their safety, simple preparation, and effectiveness, especially in the development of personalized cancer vaccines, which have shown great advantages. However, the current peptide-based vaccines often require artificial synthesis and intricate delivery technology, which increases the cost and complexity of preparation. Methods: Here, we developed a simple technique for combining a peptide and a delivery system using the natural secretion system of bacteria. Specifically, we biosynthesized an antigenic peptide in bacteria, which was then extracellularly released through the bacterial secretory vesicles, thus simultaneously achieving the biosynthesis and delivery of the peptide. Results: The system utilizes the natural properties of bacterial vesicles to promote antigen uptake and dendritic cell (DC) maturation. Therefore, tumor-specific CD4 + Th1 and CD8 + cytotoxic T lymphocyte (CTL) responses were induced in TC-1 tumor-bearing mice, thereby efficiently suppressing tumor growth. Conclusion: This research promotes innovation and extends the application of peptide-based vaccine biosynthesis technology. Importantly, it provides a new method for personalized cancer immunotherapy that uses screened peptides as antigens in the future. Keywords: tumor immunization, peptide vaccine, outer membrane vesicle, delivery system Immunotherapy is considered a potential cancer treatment strategy, 1 in which therapeutic cancer vaccines are an important factor. 2 The effectiveness of therapeutic cancer vaccines has been demonstrated in a variety of cancer types. At present, the therapeutic cancer vaccine strategy targeting screened personalized neoantigens has gradually shown great application prospects. 3 Enabling the simultaneous display of multiple tumor antigens by linking antigens using a plug-and-play system may be a valuable approach for the development of personalized tumor vaccines against complex and heterogeneous tumor antigens. 4,5 Recently, peptide-based vaccines have received increasing attention in both infectious disease and cancer research fields because of their convenient preparation, high safety, and favorable immunogenicity. Peptide-based vaccines can be intelligently designed to target specific MHC molecules for efficient presentation, thereby enhancing B-cell and T-cell responses. An advantage of peptide-based vaccines is that they are easy to synthesize, eliminating the need for many tedious processes, such as the expression and purification of vaccine antigens and in vitro transcription of nucleic acid vaccines. Peptide-based vaccines can be easily obtained through artificial synthesis, and have high purity. However, although artificially synthesized peptides are convenient, they have a higher cost. In addition, peptide-based vaccines generally require a suitable delivery system to protect and deliver the peptide, which increases the cost and complexity of peptide-based vaccine preparation. Currently, more than 500,000 women are diagnosed with cervical cancer each year, and the disease causes more than 300,000 deaths worldwide. In most cases, high-risk subtypes of human papilloma virus (HPV) are the cause of the disease. However the disease is largely preventable. 6 We have also conducted some previous research on the treatment of this disease and we established a vaccine technology platform based on norovirus virus-like particles (VLPs) displaying personalized antigens. 7 -Abstract Truncated-

Peptide Vaccination – a Novel Therapeutically Option for Cancer Patients

Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65.

Vaccination with A Dna Vaccine Based on Human Psca and Hsp70 Adjuvant Enhances the Antigen-Specific Cd8(+) T-Cell Response and Inhibits the Psca(+) Tumors Growth in Mice

Vaccination with the Repeat Β-Hcg C-terminal Peptide Carried by Heat Shock Protein-65 (HSP65) for Inducing Antitumor Effects

Immunization with a Recombinant GnRH Vaccine Fused to Heat Shock Protein 65 Inhibits Mammary Tumor Growth in Vivo.

Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide.

Construction of a novel DNA vaccine against β-hCG and its anti-tumor effects combined with adjuvant GM-CSF

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

Ten tandem repeats of β-hCG 109–118 enhance immunogenicity and anti-tumor effects of β-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65

The Fusion Protein of Hsp65 with Tandem Repeats of Beta-Hcg Acting As A Potent Tumor Vaccine in Suppressing Hepatocarcinoma

Peptide-Based Therapeutic HPV Cancer Vaccine Synthesized via Bacterial Outer Membrane Vesicles

Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid

A novel vaccine targeting gastrin-releasing peptide: efficient inhibition of breast cancer growth in vivo.

Modulatory Effects of Tumor-Derived Heat Shock Protein in DNA Vaccination Against Nasopharyngeal Carcinoma

Antitumor immunity against hCGβ induced by a tumor cell vaccine modified with a fusion gene of hCGβ and polyarginines

Vaccination with Synthetic Long Peptide Formulated with CpG in an Oil-in-water Emulsion Induces Robust E7-specific CD8 T Cell Responses and TC-1 Tumor Eradication

Co-assembled and Self-Delivered Epitope/cpg Nanocomplex Vaccine Augments Peptide Immunogenicity for Cancer Immunotherapy

Vaccination with a Potent DNA Vaccine Targeting B-cell Epitopes of Hgrp Induces Prophylactic and Therapeutic Antitumor Activity in Vivo.

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

Strong Humoral Response Elicited by A Dna Vaccine Targeting Gastrin-Releasing Peptide with Optimized Adjuvants Inhibits Murine Prostate Carcinoma Growth in Vivo

Cell-Penetrating Peptide Enhanced Antigen Presentation for Cancer Immunotherapy.